Kazia Therapeutics
KZIA
7 hedge funds and large institutions have $324K invested in Kazia Therapeutics in 2019 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.
40% more funds holding
Funds holding: 5 → 7 (+2)
0.17% more ownership
Funds ownership: 1.55% → 1.72% (+0.17%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
11% less capital invested
Capital invested by funds: $365K → $324K (-$41K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$62.9K |
| 2 |
Morgan Stanley
New York
|
+$5.53K |
| 3 |
SPIA
Steward Partners Investment Advisory
New York
|
+$1.84K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$2.46K |
KZIA Hedge Fund Activity: Q2 2019 in Review
7 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Kazia Therapeutics (KZIA) for Q2 2019, worth a combined $324K — down 11% from $365K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new KZIA positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $62.9K. The largest seller was UBS Group, cutting an estimated $2.46K.
- 7 institutional investors held Kazia Therapeutics (KZIA) as of Q2 2019, up from 5 in Q1 2019.
- Funds reported $324K of Kazia Therapeutics stock for Q2 2019, down 11% quarter-over-quarter.
- 2 funds opened new Kazia Therapeutics positions in Q2 2019 and 0 closed out, a net change of +2 holders.
- The largest Kazia Therapeutics buyer in Q2 2019 was Citadel Advisors, an estimated $62.9K added.
- The largest Kazia Therapeutics seller in Q2 2019 was UBS Group, an estimated $2.46K sold.
Based on aggregated 13F filings for Q2 2019.